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Abstract Phosphate triester derivatives of the anti-neoplastic 
alkyi iyso phospholipid (ALP) have been prepared as novel poten- 
tial therapeutic agents. In particular, symmetrical phosphate 
triesters have been prepared, using phosphorochloridate chemis- 
try. The compounds have been fully characterised by a range of 
techniques, and assayed for their inhibition of DNA synthesis by 
mammalian cells in culture. The compounds are generally inhib- 
itory towards DNA synthesis in the pM range. However, the 
magnitude of the effect varies greatly with the phosphate struc- 
ture; alkynyl and glycol substituted phosphates being especially 
potent. 
In a recent paper [13] we described our initial results regarding 
the synthesis of some novel ALPs, modified in the phosphate 
region. It was a notable and surprising observation that simple 
dialkyl blocked phosphate derivatives are active in vitro and 
that simple structure activity trends appear to operate. In this 
paper we describe the synthesis of some novel ALPs, further 
modified in the phosphate region in the hope of improving 
activity at lower concentration, and we discuss their evaluation 
in vitro. In particular we study the effect on anti-cancer activity 
of substitution within the alkyl-phosphate r gion. 
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2. Materials and methods 
1. Introduction 
It is known that certain phospholipid analogues may have an 
anti-cancer action; the alkyl lysophospholipids (ALPs; 1 in Fig. 
1) are synthetic molecules with biological activity [1,2,3]. Whilst 
the details of the mechanisms of action of these compounds 
remain to be elucidated, the cytotoxic effects of  lysophospho- 
lipids are thought o involve several processes [4]. In high con- 
centrations lysophospholipids have a cytolytic detergent action, 
and may form extracellular micelles which act as sinks for 
cholesterol and other essential lipids. Below the critical micelle 
concentration (CMC), lysophospholipids may be incorporated 
into cell membranes and modify their structure and function 
[5]. Some of these compounds may reach the cell interior and 
interfere with some of the processes involved in membrane 
signal transduction [6] and this last process may be of particular 
importance with regard to anti-proliferative effects. Vogler and 
co-workers [7] have examined the effect on proliferation inhibi- 
tion, estimated by thymidine incorporation and clonogenic as- 
says, of  a series of glycerol phosphocholine analogues with 
varying substitutions in the sn-1 and sn-2 positions. 
In the work reported in this paper, we have investigated the 
effect of a series of phosphate substituted ALPs on cell prolif- 
eration, using a radio-thymidine incorporation assay to meas- 
ure DNA synthesis. Cells were exposed to ALP analogues in 
concentrations below the CMC and DNA synthesis monitored 
after a 24-h exposure. 
Given our experience in the improvement of the therapeutic 
performance of bio-active nucleosides by suitable phosphate 
modification [8,9,10,11,12] we wondered if a similar strategy 
might lead to enhancement of the properties of the parent ALP. 
*Corresponding author. Fax: (44) (1222) 87-4537. 
All experiments involving water-sensitive r agents were carried out 
under scrupulously dry conditions. Where needed, anhydrous olvents 
and reagents were obtained in the following ways: triethylamine and 
pyridine were refluxed over Call2 for several hours and distilled. Pyri- 
dine was further stored over KOH pellets. Diethyl ether was refluxed 
over calcium hydride for several hours and further dried over activated 
4A molecular sieves. Phosphoryl chloride was distilled at atmospheric 
pressure. Commercially available Merck kieselgel was used for the 
preparative TLC and the components were visualised by iodine. Col- 
umn chromatography was carried out using Woelm silica (32-63 mesh) 
as the stationary phase. The ratio of silica-compound varied between 
50:1 and 100:1 (w/w). Phosphorus-31 NMR spectra were recorded on 
a Jeol FX90Q instrument operating at 36.2 MHz and are reported in 
units of ~ relative to 85% phosphoric acid as external standard, positive 
shifts are downfield. Carbon-13 NMR spectra were recorded on a 
JEOL FX270 spectrometer operating at 67.9 MHz, or a Bruker AM360 
instrument operating at 90.6 MHz. Shifts are expressed in units of 
relative to CDC13 at 77.20 ppm. Both phosphorus-31 and carbon-13 
NMR spectra were proton noise decoupled and all signals were singlets 
unless otherwise stated. H-1 NMR spectra were recorded on a JEOL 
FX270 spectrometer operating at 270 MHz, or a Bruker AM360 ma- 
chine operating at 360 MHz and are reported in units of 8 relative to 
internal CHCI3 at 7270 ppm unless otherwise stated. All NMR spectra 
were recorded in CDC13. Mass spectra were recorded in Fast Atom 
Bombardment (FAB) mode on a VG 7(~250 spectrometer. 
2.1. 3-O-hexadecyl-2-O-methyl-rac-glycerol (2) 
This was prepared entirely as recently described by us [13]. 
2.2. 3-O-hexadecyL2-O-methyl-rac-glyceroLbis 
(methyl glyeolyl)phosphate (3a) 
l-O-Hexadecyl-2-O-methyl-rae-glycerol (2) (140 rag, 0.43 mmol) was 
dissolved in pyridine (20 ml), and di(methyl glycolyl)phosphoro- 
chloridate (352 mg, 1.35 mmol) was added dropwise with vigorous 
stirring, after stirring for 5 h at ambient temperature, the reaction was 
quenched with water (2 ml), and the solvent was removed under re- 
duced pressure. The resulting oil was isolated by preparative thin layer 
chromatography using 5% methanol in chloroform as eluant o give the 
product as an oil (151 mg, 57.6%); ~p-2 ; ~ 0.89 (3H, t, w-CHs), 1.26 
(26H, bs, CH2 × 13), 1.60 (2H, m, OCH2CH2R), 3.44-3.53 (8H, m, 
CHCHzOCH2, OCH3), 3.80 (6H, s, CH3OCO), 4.20~,.45 (2H, m, 
CHCH2OP ), 4.72 (4H, m, COCH2OP); FAB MS 577 (MH++Na, 34), 
555.3289 (MH +, C2~H52OIoP requires 555.3298, 54), 313 (C20H410~, 25). 
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2.3. 3-O-Hexadecyl-2-O-methyl-rac-glycerol-bis{(s)-(-)-methyl 
lactyl}phosphate (3b) 
This was prepared by an analogous method to (3a). Thus, from the 
condensation fdi {(s)-(-)-methyl lactyl} phosphorochloridate (815 mg, 
2.83 mmol) and (2) (128 mg, 0.39 mmol) the product was obtained as 
an oil (72 mg, 31.6%) ; ~p -5.8; d, 0.85 (3H, t, o-CH3), 1.26 (26H, bs, 
CH2 x 13), 1.59-1.65 (8H, m, OCH2CH:R, CH3CH x 2), 3.47 (8H, m, 
CHCH~OCH2, OCH3), 3.78 (6H, s, CH~OCOx2), 4.21 (2H, m, 
CHCHzOP), 4.93 (2H, m, COCHOP); FAB MS 605 (MH÷+Na, 7), 
583.3591 (MH +, C28H56OIoP requires 583.361 I, 70), 497 (C24HsoOsP +,
8), 313 (C2oH4~O~, 10), 271 ((CH3OCOCHCH30)2PO:H~, 50), 185 
(CH3OCOCHCH3OPO3H3 +, 20), 87 (C4H70~, 40). 
2.4. 3-O-Hexadecyl-2-O-methyl-rac-glycerol-bis 
(2-propyn-l-yl)phosphate (3e) 
This was prepared by an analogous method to (3a). Thus, from the 
condensation of bis(propargyl)phosphorochloridate (268 mg, 1.39 
mmol) and (2) (122 rag, 0.37 retool) the product was obtained as an oil 
(58 mg, 32%); de -2; d, 0.86 (3H, t, o9-CH3), 1.20-1.33 (26H, m, 
CH: × 13), 1.51 (2H, m, OCH2CH~R), 2.60 (2H, m, C=CH), 3.38 3.53 
(8H, m, CHCH:OCH2, OCHs), 4.09-4.28 (2H, m, CHCH2OP), 4.65 
4.78 (4H, m, C-=CCH~ x 2); FAB MS 487.3186 (MH +, C26Ha806P 
requires 487.3189, 100), 449 (C24H4~O6P +, 10), 313 (C~0H4tO~, 15), 175 
((HC -= CCH20)2PO2H +, 27), 137 (HC-=CCH2OPO3H~, 70). 
2.5. 3-O-Hexadecyl-2-O-methyl-rac-glycerol-bis 
(3-butyn-l-yl)phosphate (3(1) 
This was prepared by an analogous method to (3a). Thus, from the 
condensation of bis(3-butyn-l-yl)phosphorochloridate (165 mg, 0.75 
mmol) and (2) (123 mg, 0.38 mmol) the product was obtained as an oil 
(85 mg, 44%) ; de -3 ; d. 0.85 (3H, t, o)-CH3), 1.22 1.35 (26H, m, CH2 
x 13), 1.51 (2H, m, OCH2CH~R), 2.02 (2H, m, HC~-C , J --- 2.6 Hz), 
2.52 (4H, m, C ~ CCH2, J = 2.7 Hz), 3.38-3.56 (8H, m, CHCHzOCHz, 
OCH3), 4.05-4.25 (6H, m, CH2OP, CHCHzOP) ; FAB MS 537 
(MH++Na, 4), 515.3549 (MH ÷, CzgHszO6P requires 515.3502, 100), 463 
(C24H4806 P+, 3), 313 (C20H410~, 18), 203 ((HC~CCH2CH20)2- 
PO~, 21), 151 (HC-=-- CCH2CH~OPO3H3 P+, 30). 
2.6. 3-O-Hexadecyl-2-O-methyl-rac-glycerol-bis 
(glycidol)phosphate (3e) 
This was prepared by an analogous method to (3a). Thus, from the 
condensation fbis(glycidol)phosphorochloridate (290 mg, 1.30 mmol) 
and (2) (136 mg, 0.42 mmol) the product was obtained as an oil (33 mg, 
15.2%); de 0; dn 0.83 (3H, t, o)-CH3), 1.20-1.35 (26H, m, CH2 x 13), 1.50 
(2H, m, OCH~CH~R), 2.63 (4H, bs, oxiryl-CHzOP x 2), 3.21-3.46 (8H, 
m, CHCH~OCH2, OCH3), 4.17 (2H, m, CHzOP); E1 MS 545 
(MH++Na, 70), 523 (MH ÷, 36), 467 (C23H48OrP +, 3), 313 (C~0H410~, 7), 
211 ((OCH:CHCH20)2PO2H~, 13), 155 (OCH2CHCH2OPO3H~E 15), 
57 (OCH2CHCH~, 100). 
2.7. 3-O-Hexade~yl-2-O-methyl-rac-glycerol-bis(1,2-O- 
isopropylidene-rac-glycerol-3-yl)phosphate (3t") 
This was prepared by an analogous method to (3a). Thus, from the 
condensation of bis(1,2-O-isopropylidene-rac-glycerol-3-yl)phos- 
phorochloridate (175 mg, 0.75 mmol) and (2) (123 mg, 0.38 mmol) 
the product was obtained as an oil (79 mg, 28.9%); dp -1.8; dH 0.88 
(3H, t, co-CH3), 1.19 1.35 (26H, m, CH2x 13) 1.37 (6H, s, ipr- 
CH3), 1.42 (6H, s, ipr-CH3), 1.55 (2H, m, RCH2CH20), 3.35-3.55 (8H, 
m, CHCHzOCH 2, OCH3), 3.82 (2H, m, CHCH2OP x 2), 4.00-4.35 
(10H, m, OCH2CHO x 2, CH2OP x 3) ; FAB MS 661 (MH÷+Na, 2), 
639.4133 (MH ÷, C3:H640]0P requires 639.4237, 15), 525 (C26Hs408 P+, 
10), 328 ((C6HIIO3)2POzH ~, 3), 313 (C2oH4102 +,15), 211 (C6H~2Oe, P--, 
47), 115 (C6HI]O~, 100). 
2.8. 3-O-Hexadecyl-2-O-methyl-rac-glycerol-bis 
[2- (hydroxymethyl)tetrahydropyranyl]phosphate (3g) 
This was prepared by an analogous method to (3a). Thus, from the 
condensation of bis[2-(hydroxymethyl)tetrahydropyranyl]phosphoro- 
chloridate (337 rag, 1.08 mmol) and (2) (142 rag, 0.43 mmol) the 
product was obtained as an oil (137 mg, 52.1%); dp 0; d, 0.88 (3H, t, 
o)-CH3), 1.21-1.36 (30H, m, CH2 x 13, pyran-CH, x 2), 1.55 (8H, m, 
pyran-CH2x2), 1.82 (2H, m, RCH2CH20), 3.37-3.58 (12H, m, 
CHCH2OCH2, OCH3, pyran-CH20 × 2), 3.92-4.18 (8H, m, pyran-CH 
x 2, CH2OP x 3) ; FAB MS 607.4287 (MH +, C32H6408P requires 
607.4339, 40), 509 (C26H5407 p+, 6), 295 ((C6HIlO)2PO2H~, 11), 197 
(C6HHOPO3H~, 14), 99 (C6H,IO~, 100). 
2.9. 3-O-Hexadecyl-2-O-methyl-rac-glycerol-bis 
(monomethyl ethylene glycolyl) phosphate (3h) 
This was prepared by an analogous method to (3a). Thus, from the 
condensation of bis(monomethyl ethylene glycolyl)phosphoro- 
chloridate (784 mg, 3.51 mmol) and ([2) (164 mg, 0.50 mmol) the 
product was obtained as an oil (43 mg, 22%); dp -2 ; dH 0.87 (3H, t, 
to-CH3) , 1.18-1.34 (26H, m, CH 2 × 13), 1.54 (2H, m, OCH2CH2R), 
3.37-3.62 (18H, m, OCH2CH2OP x 2, CH, RCH2OCH2, OCH3 x 3), 
4.05-4.25 (6H, m, OCH2CH2OP x 2, CHCH:OP); FAB MS 527.3702 
(MH +, C26H56OsP requires 527.3713, 40), 469 (C23H5oO7 P+, 3), 313 
(C20H4102 +, 4), 215 ((CH3OCH2CHzO)2PO2H2 +, 26), 157 (CH3OCH 2 
CH2OPO3H~, 23), 59 (CH3OCH2CH~, 100). 
2.10. 3-O-HexadecT1-2-O-methyl-rac-glycerol-bis 
(monomethyl diethylene glycolyl)phosphate (3i) 
This was prepared by an analogous method to (3a). Thus, from 
the condensation of bis(monomethyl diethylene glycolyl)phos- 
phorochloridate (784 rag, 3.51 mmol) and (2) (164 mg, 0.50 mmol) the 
product was obtained as an oil (107 mg, 34.7%); de -4; d. 0.86 (3H, 
t, m-CH3), 1.18 1.35 (26H, m, CH 2 x13), 1.54 (2H, m, OCH2CH2R ), 
3.36 (6H, s, glycol-OCH 3x 2), 3.38-3.73 (22H, m, OCH2CH2OP x 2, 
CH3OCHzCHO x 2, CH, RCH2OCH2, OCH 3 x 3), 4.04-4.23 (6H, m, 
OCH2CH2OP x 2, CHCH2OP); FAB MS 637 (MH*+Na, 35), 615.4200 
(MH +, C30H64OIoP requires 615.4237, 60), 583 (M+-OCH3, 2), 513 
(C25H5408 p+ , 3), 313 (C20H4/O~, 4), 303 ((CH3OCH 2 
CH~OCH2Ct-120)2PO2H ~, 15), 201 (CH3OCH2CH2OCH2CH2OPO3H ;, 
10), 103 (CH3OCH2CHeOCH2CH2 +, 100), 59 (CH3OCH2CH2 +, 
88). 
2.11. 3-O-Hexadecyl-2-O-methyl-rac-glycerol-bis 
(monomethyl triethylene glycolyl)phosphate (3j) 
This was prepared by an analogous method to (3a). Thus, from the 
condensation of bis(monomethyl triethylene glycolyl)phosphoro- 
chloridate (650 mg, 1.59 mmol) and (2) (140 mg, 0.43 mmol) the product 
was obtained as an oil (134 mg, 47.5%); dp -2 ; d, 0.86 (3H, t, co-CHs), 
1.21-1.35 (26H, m, CH 2 x 13), 1.55 (2H, m, OCHeCH2R), 3.37 (6H, s, 
glycl-OCH3), 3.38-3.73 (28H, m, OCH2CH2OPx 2, CH2CH2Ox 2, 
OCH2CH2Ox2, CH, RCHzOCH2, OCHs), 4.08-4.22 (6H, m, 
OCH2CH2OP x 2, CHCH2OP); FAB MS 703.4662 (MH ÷, C34H72OI2P 
requires 703.4761,14), 671 (M+-OCHs, 1), 557 (CzTHs~OgP +,2), 391 
((CH3OCH2CH2OCH:CH2OCH2CHzO)2PO2H~, 5), 313 (C20H4tO~, 3), 
245 (CH3OCH2CH2OCH2CH2OCH2CH2OPO3H~, 7), 147 (CH3OCH2- 
CHzOCHzCHzOCHzCH+z, 32), 103 (CHsOCH2CH2OCHzCH2 ÷, 30), 89 
(CH3OCH2CH2OCH~, 17), 59 (CH3OCHzCH ~, 100). 
[RO]2POCI 
O-Ct6H33 r--o-c16 H33 pyr, 20 °c, 5h ~--O-Cle H33 
P~/O'X,~ O-Me I-oO2,,, Lo o 
RO OR 
~= 
R= 
R= 
O O 
CH3 
3a 31) 3¢ 3(/ 
o 
= si 
Fig. 1. Synthetic route to lipid analogues. 
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.'.12. Tritiated thymidine incorporation assay 
This assay was conducted entirely as we have recently described 
] 13], using an exposure period of 24 h, and a labelling time of 30 rain. 
Ceils between passages 24 and 34 were used, and the reference com- 
i~ound hexadecyl phosphatidyl choline (Sigma) was included in the 
,eries of experiments a  a source for comparison of the effectiveness of
he agents tested. 
~. Results 
The synthetic route adopted to the lipid analogues was en- 
:irely as recently described by us for simple dialkyl phosphate 
:riester ALPs [13]. Thus, 1-O-hexadecyl-2-O-methyl-rac-glyc- 
zrol (2) was prepared from 2,3-O-isopropylidene-rac-glycerol 
in 4 steps in an overall yield of 31%. This material was used in 
a series of parallel reactions with a wide variety of dialkyl 
phosphorochloridates (Fig. 1), which were prepared in one step 
by the reaction of phosphoryl chloride with 2 equivalents of the 
appropriate alcohol, in the presence of triethylamine. The final 
products (3a-j) were isolated by preparative thin layer chroma- 
tography in yields ranging from 15% to 58%. All materials were 
pure by chromatographic and spectroscopic methods, the latter 
including P-31, H-1 and C-13 NMR and high resolution mass 
spectrometry. Carbon- and phosphorus-NMR data for all final 
products (3a-j) are given in Tables 1 and 2. 
4. Discussion 
Each of the ALP derivatives (3a-j) and the reference com- 
pound hexadecyl phosphatidyl choline (CI6PC) were tested for 
their ability to inhibit the incorporation of tritiated thymidine 
into the DNA of mammalian cells in tissue culture, using meth- 
ods we have described [13]. The data are summarised in Table 
3 and indicate a dose-dependent i hibition of thymidine incor- 
poration for many of the ALP analogues tudied. Especially 
potent compounds include those containing alkynyl (3e and 3(I) 
and glycol (3h-3j) structures. In these cases it is instructive to 
compare the data to that reported by us for simple alkyl phos- 
phate analogues [13] where we found a sharp cut-off in activity 
Table 1 
Carbon-13 and phosphorus-31 NMR data for compounds (3a-3f) 
3a 3b 3c 3d 3e 3f 
Alkyl 
CI 14.3 14.2 14.2 14.2 14.2 14.2 
C2 22.9 23.8 22.8 22.8 22.8 22.8 
C3-13 29.8 29.9 29.7-30.0 29.4-29.8 29.4-29.8 29.4-29.8 29.5-29.8 
C14 26.5 26.4 26.1 26.2 26.1 26.2 
C15 32.4 32.5 32.0 32.0 32.0 32.0 
C16 71.1 67.8 69.2 69.3 68.4 69.3 
G&cerol 
CI 72.4 72.7 72.0 72.0 71.9 72.01 
C2 78.47 79.4 78.977 79.07 78.87 78.97 
C3 66.56 67.0 67.36 67.16 67.26 67.26 
OMe 58.2 58.0 58.2 58.1 58.l 58.2 
P-OR 
CI" 66.3 72.9 55.44 65.53 50.1 67.8 
C2" 174.2 19.6 79.02 20.77 50.0 74.1 a 
C3" 60.9 174.2 76.5 79.4 44.6 66.3 
C4" 53.4 70.5 110.0 
C5" 25.4 
C6" 26.8 
5p -2 -5.8 -2 -3 0 - 1.8 
All spectra re recorded in CDC13. Data are presented as 5 in ppm, with l-O-alkyl chains numbered from the. terminus. All spectra were recorded 
using proton decoupling. In the case of carbon data, phosphorus coupling constants in Hz are superscripted. 
0 02CH3 
3 II 1 4 II 
C I"IsO--C--C I-L 2 (3a) ,  C H30- -C- -C  H (3b) 
2 3 1 
3 2 1 4 3 2 1 
H C----C--C H 2 (3¢), H C~_C--C 1-12C I-I 2 (3d)  
3 2 1 
3 a ~ ,---.,--CH~ 
k----'/--C H2, / ~ ~ 
040 
0 s C '~CI% 6 
(3e) (30 
The side-chain umbers correspond to their assignments in the ~3C NMR Table l. 
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for compounds with alkyl-phosphate chains longer than 2 car- 
bon atoms. Thus, the dipropyl compound [13] displayed 17% 
(+ 2) inhibition of thymidine incorporation at 100/2M, whilst 
we now note the somewhat similar propargyl analogue (3e) to 
show 90% (+ 2%) inhibition. Similarly, the previous dibutyl 
compound isplayed 0% (+ 15) whilst the butynyl analogue 
(3d) shows 96% (+ 1%) inhibition. It is very clear that, whilst 
a strict size limit operates for the simple dialkyl analogues, this 
appears not to be the case for the alkynyl analogues, at least 
within the limits herein described. Of course, the alkynyl sys- 
tems are far more constrained ina conformational sense, being 
unable to adopt much of the vast conformational space availa- 
ble to the simple alkyl systems of analogous length - -  this may 
be one explanation for the apparent difference in steric con- 
straints operational in the two series. Furthermore, the alkynyl 
terminus i inherently far more polar in nature than the corre- 
Table 2 
Carbon-13 and phosphorus-31 NMR data for compounds (3g-3j) 
3g 3h 3i 3j 
Alkyl 
C1 14.3 14.2 14.2 14.2 
C2 22.9 22.8 22.8 22.8 
C3-13 29.5-29.9 29.4-29.8 29.4-29.8 29.4-29,8 
C14 26.2 26.2 26.2 26.1 
C15 32.1 32.0 32.0 32.0 
C16 69.7 69.5 69.6 69.5 
Glycerol 
CI 72.0 72.0 72.0 72.0 
C2 79.08 78.9 s 78.97 78.97 
C3 66.76 66.8 66.78 66.77 
OMe 58.3 58.1 58.1 58.2 
P-OR 
CI" 70.55 71.47 66.84 66.83 
C2" 76.2 ~ 66.8 70.2 71,95 
C3" 27.7 59.0 70.6 70.68 
C4" 23.0 72.0 70.67 
C5" 25.9 - 59.1 70. I
C6" 68.4 70.0 
C7" - 59.1 
dp 0 -2 -4 -2 
All spectra re recorded inCDCI 3. Data are presented as~ in ppm, with 
l-O-alkyl chains numbered from the terminus. All spectra were re- 
corded using proton decoupling. In the case of carbon data, phospho- 
rus coupling constants in Hz are superscripted. 
4 
6 Ha 
(3g)  
3 2 1 
C H3OC 1-12C H 2 (3h)  
5 4 3 2 1 
C H3OC H2C H2OC I-i,2C H 2 (3 i )  
7 6 5 4 3 2 1 
C i-'130C1-12C H20C1-12C !-120C1"i2C1-12 (3 j )  
The side-chain umbers correspond to their assignments in the ]3C 
NMR Table 2. 
C. McGuigan et al./FEBS Letters 372 (1995) 259-263 
Table 3 
Inhibition by ALP derivatives oftritiated thymidine incorporation by 
cells in vitro 
Compound %1 @ 100/tM %1 @ 10,uM 
3a 26 (1.5) 11 (6.1) 
3b 6 (2.2) 13 (2.3) 
3e 90 (1.8) 3 (10.3) 
3d 96 (0.8) 3 (8.5) 
3e 25 (5.6) 10 (2.8) 
3f 40 (2.9) 0 (1.8) 
3g 48 (10.4) 8 (3.4) 
3h 99.7 (0.03) 12.1 (4.8) 
3i 79 (7.6) 0 (5.4) 
3 i 99.6 (0.04) 22 (2.9) 
C16PC* 60 (6) 5.4 (5.5) 
The data shown are calculated from the means of quadruplicate meas- 
urements oftritiated thymidine incorporation i to trichloroacetic a id- 
insoluble material by sub-confluent CNCM-I222 cells, compared to 
appropriate solvent controls, with standard eviations in brackets. 
*indicates hexadecyl phosphatidyl choline was included as internal con- 
trol. 
sponding methyl(ene) terminus of the simple alkyl systems, 
which may again lead to the apparently different steric con- 
straints. To some extent his latter explanation is more consist- 
ent with the even more striking data on the glycol (3h), digol 
(3i) and trigol (3j) series herein described. Thus, the first of 
these may be rather similar in a steric sense to the simple butyl 
compound previously described [13]. However, as noted above, 
whilst the butyl compound is essentially inactive in this assay, 
the glycol analogue (3h) is potent, with >99% inhibition at 100 
/.tM, Moreover, the trigol (3j), which might have been expected 
to be inactive from our previous (steric) structure-activity rela- 
tionships is very potent, with >99% inhibition at 100/.tM and 
35% at 10/~M. This material is thus perhaps 5-10-fold more 
potent han the reference compound C16PC. 
The great steric demands, and most likely high flexibility of 
these glycol systems indicates that the presence of heteroatoms 
within such alkyl chains is able to entirely overcome the severe 
steric constrains operational for the simple alkyl phosphate 
analogues. As noted above for the alkynyl analogues, the polar- 
ity conferred by the heteroatoms may be instrumental in this 
phenomena, lthough the precise mechanism in operation re- 
mains unclear. 
In conclusion, we note that substituted alkyl phosphate 
triester ALP derivatives inhibit thymidine incorporation by 
mammalian cells in tissue culture. The potency of inhibition 
varies greatly with the nature of the phosphate substituents, 
with alkynyl and glycol groups being especially efficacious. In 
some cases, particularly for a trigol derivative, the in vitro 
activity appears to exceed that of the reference compound by 
as much as an order of magnitude. Whilst the precise mecha- 
nism &action of these materials remains unclear, it is apparent 
that activity is tunable by changing the phosphate structure, 
and that the apparent severe steric onstraints on the phosphate 
region for simple alkyl phosphates do not apply for substituted 
analogues. This suggests good possibilities for further optimisa- 
tion of the leads we describe, and the prospect of agents emerg- 
ing with improved therapeutic efficacy over existing lipid drugs. 
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